OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
Collaborative T, Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton C, Bacon S, Hickman G, Inglesby P, Bates C, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson E, Hulme W, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wong AY, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Goldacre B. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart 2021, 8: e001784. PMID: 34785588, PMCID: PMC8595296, DOI: 10.1136/openhrt-2021-001784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsBlood CoagulationBlood Coagulation TestsCOVID-19Drug MonitoringDrug PrescriptionsDrug SubstitutionDrug UtilizationEnglandFactor Xa InhibitorsFemaleHumansMaleMiddle AgedPatient SafetyPractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareRetrospective StudiesRisk AssessmentRisk FactorsState MedicineWarfarinConceptsWarfarin patientsNational Health ServiceCOVID-19 pandemicNational guidanceCare home residencyINR test resultsRenal function testsFrequent blood testingSafety alertsRoutine clinical dataAtrial fibrillation diagnosisElevated INRMedication changesOral anticoagulantsAnticoagulant therapyCohort studyAppropriate patientsINR testsFunction testsBlood testingPrimary careClinical dataDOACPatientsWarfarinAssociation between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Wong A, Tomlinson L, Brown J, Elson W, Walker A, Schultze A, Morton C, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch C, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis H, Mehrkar A, Cockburn J, McDonald H, Mathur R, Wing K, Forbes H, Eggo R, Evans S, Smeeth L, Goldacre B, Douglas I. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal Of Hematology & Oncology 2021, 14: 172. PMID: 34666811, PMCID: PMC8525065, DOI: 10.1186/s13045-021-01185-0.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPopulation-based cohort studyCOVID-19-related outcomesSevere COVID-19Oral anticoagulantsCohort studyHazard ratioLower riskNegative control outcome analysisSevere COVID-19 diseaseNon-valvular atrial fibrillationPrimary care dataCOVID-19 outcomesCOVID-19COVID-19 diseaseNegative control outcomesDOAC usersOpenSAFELY platformWarfarin usersHospital admissionAtrial fibrillationClinical evidenceCox regressionResultsA totalOutcome analysis